These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528 [TBL] [Abstract][Full Text] [Related]
5. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients. Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446 [No Abstract] [Full Text] [Related]
6. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Massry SG; Goldstein DA; Malluche HH Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981 [No Abstract] [Full Text] [Related]
7. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations. Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373 [TBL] [Abstract][Full Text] [Related]
8. Long-term therapy of uremic osteodystrophy in adults with calcitriol. Moorthy AV; Harrington AR; Mazess RB; Simpson DP Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893 [TBL] [Abstract][Full Text] [Related]
9. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125 [TBL] [Abstract][Full Text] [Related]
10. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure. Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527 [TBL] [Abstract][Full Text] [Related]
11. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy. Coburn JW; Brickman AS Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852 [No Abstract] [Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
13. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients. Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D Bone; 1992; 13(5):369-77. PubMed ID: 1419378 [TBL] [Abstract][Full Text] [Related]
14. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3. Chan JC; Lovinger RD; Mamunes P Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489 [TBL] [Abstract][Full Text] [Related]
15. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium. Winney RJ; Bone JM; Anderson TJ; Robson JS Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593 [No Abstract] [Full Text] [Related]
16. 1,25-Dihydroxycholecalciferol in dialysed patients with clinically asymptomatic renal osteodystrophy. A controlled study. Fischer JA; Binswanger U Contrib Nephrol; 1980; 18():82-91. PubMed ID: 7353381 [TBL] [Abstract][Full Text] [Related]
17. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3. Pierides AM; Skillen AW; Ellis HA J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610 [TBL] [Abstract][Full Text] [Related]
18. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3. Voigts AL; Felsenfeld AJ; Llach F Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827 [TBL] [Abstract][Full Text] [Related]
19. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol. Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103 [TBL] [Abstract][Full Text] [Related]
20. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]